Is LivaNova PLC (LIVN) overvalued? · P/E 41, rev $752.8M
LivaNova PLC (LIVN) is a medical devices company listed on NASDAQ.
This page asks whether LivaNova PLC (LIVN) looks expensive on cached numbers — not a short thesis.
Latest reported LIVN revenue for 2026-06-30 was $752.8M. Net income was $130.9M. LIVN currently screens at market cap $4.40B and trailing P/E 40.8.
LIVN currently screens at market cap $4.40B and trailing P/E 40.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LIVN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LIVN stock page for the full model, not this heading.
Not investment advice.